Related Experiment Video
Updated: Jan 3, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Delayed vasopressor initiation is associated with increased mortality in patients with septic shock
Daniel Colon Hidalgo1, Jaimini Patel2, Dalila Masic2
1Department of Medicine, Loyola University Medical Center, 2160 S 1st Ave, Maywood, IL, USA.
Purpose:
Mortality rate for septic shock, despite advancements in knowledge and treatment, remains high. Treatment includes administration of broad-spectrum antibiotics and stabilization of the mean arterial pressure (MAP) with intravenous fluid resuscitation. Fluid-refractory shock warrants vasopressor initiation. There is a paucity of evidence regarding the timing of vasopressor initiation and its effect on patient outcomes.
Materials And Methods:
This retrospective, single-centered, cohort study included patients with septic shock from January 2017 to July 2017. Time from initial hypotension to vasopressor initiation was measured for each patient. The primary outcome was 30-day mortality.
Results:
Of 530 patients screened,119 patients were included. There were no differences in baseline patient characteristics. Thirty-day mortality was higher in patients who received vasopressors after 6 h (51.1% vs 25%, p < .01). Patients who received vasopressors within the first 6 h had more vasopressor-free hours at 72 h (34.5 h vs 13.1, p = .03) and shorter time to MAP of 65 mmHg (1.5 h vs 3.0, p < .01).
Conclusion:
Vasopressor initiation after 6 h from shock recognition is associated with a significant increase in 30-day mortality. Vasopressor administration within 6 h was associated with shorter time to achievement of MAP goals and higher vasopressor-free hours within the first 72 h.
More Related Videos
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Heart Failure V: Medical Management
Antihypertensive Drugs: Vasodilators
Aneurysm IV: Nursing Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

